Company Profile For Onyx Pharmaceuticals Inc

Onyx Pharmaceuticals, Inc. (Onyx) is a biopharmaceutical company engaged in developing therapies that target the molecular mechanisms that cause cancer. With the Company’s collaborators, the Company is developing anticancer therapies. The Company’s product, Nexavar (sorafenib) tablets, being developed with the Company’s collaborator Bayer HealthCare Pharmaceuticals (Bayer), is approved by the United States Food and Drug Administration (FDA), for advanced kidney cancer and liver cancer. Nexavar is an orally available kinase and angiogenesis inhibitor and is one of a new class of anticancer treatments that target both cancer cell proliferation and tumor growth through the inhibition of key signaling pathways. As of December 31, 2008, Nexavar was approved in more than 70 countries for the treatment of advanced kidney cancer and in more than 60 countries for the treatment of liver cancer.

BRIEF: For the nine months ended 30 September 2009, Onyx Pharmaceuticals, Inc.'s revenues increased 27% to $183.1M. Net income decreased 33% to $21.7M. Revenue reflects an increase in collaboration agreement profit due to higher Nexavar revenue recognized by Bayer. Net income was offset an increase in research & development expenses, lower operating margins, higher selling, general & administrative expenses and lower investment income, net.